Related Experiment Videos
[Progress in therapeutic strategy for malignant lymphoma]
1Dept. of Hematology and Cell Therapy, Aichi Cancer Center, Nagoya, Japan.
Gan to Kagaku Ryoho. Cancer & Chemotherapy
|March 29, 2005
Summary
New therapies like rituximab have significantly advanced malignant lymphoma treatment, improving outcomes for diffuse large B-cell lymphoma and follicular lymphoma. Research continues for more effective and less toxic Hodgkin lymphoma therapies.
Area of Science:
- Hematology
- Oncology
- Immunotherapy
Context:
- Malignant lymphoma treatment has seen rapid advancements.
- New drugs and therapeutic modalities are transforming patient care.
Purpose:
- To review recent progress in therapeutic strategies for malignant lymphoma.
- To highlight the impact of novel treatments on lymphoma management.
Summary:
- Rituximab-CHOP (R-CHOP) therapy is now the standard for untreated diffuse large B-cell lymphoma.
- Prolonged progression-free survival in follicular lymphoma is observed with rituximab maintenance, R-CHOP, and stem cell transplantation.
- Standard therapies for Hodgkin lymphoma include ABVD with irradiation for early stages and ABVD for advanced stages.
Impact:
- Significant improvements in therapeutic strategies for malignant lymphoma.
- Established new standards of care, such as R-CHOP therapy.
- Ongoing clinical trials aim for enhanced efficacy and reduced toxicity in lymphoma treatment.